Search research articles
Contact Us
Filters
Showing results (31-40 of 70) with videos related to
Page
of 7
Sort By:
Cancer
|
June 19, 2013
Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission
Zaher I Chakhachiro, Rima M Saliba, Grace-Julia Okoroji, et al.
Bone Marrow Transplantation
|
October 20, 2018
Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation
Mithun Vinod Shah, Rima M Saliba, Gabriela Rondon, et al.
Haematologica
|
January 16, 2009
Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies
Carlos A Ramos, Rima M Saliba, Leandro de Pádua, et al.
British Journal of Haematology
|
June 20, 2008
Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation
Amin M Alousi, Rima M Saliba, Grace-Julia Okoroji, et al.
Blood
|
January 27, 2009
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma
Constantine S Tam, Roland Bassett, Celina Ledesma, et al.
American Journal of Hematology
|
January 23, 2023
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors
Elias J Jabbour, Koji Sasaki, Fadi G Haddad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2005
Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research
Steven Z Pavletic, Issa F Khouri, Michael Haagenson, et al.
Haematologica
|
January 29, 2008
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience
Paolo Anderlini, Rima Saliba, Sandra Acholonu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 12, 2016
Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
Paolo Anderlini, Rima M Saliba, Celina Ledesma, et al.
Blood
|
July 26, 2003
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
Naoto T Ueno, Yee Chung Cheng, Gabriela Rondón, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 70) with videos related to
Sort By:
Page
of 7
Cancer
|
June 19, 2013
Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission
Zaher I Chakhachiro, Rima M Saliba, Grace-Julia Okoroji, et al.
Bone Marrow Transplantation
|
October 20, 2018
Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation
Mithun Vinod Shah, Rima M Saliba, Gabriela Rondon, et al.
Haematologica
|
January 16, 2009
Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies
Carlos A Ramos, Rima M Saliba, Leandro de Pádua, et al.
British Journal of Haematology
|
June 20, 2008
Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation
Amin M Alousi, Rima M Saliba, Grace-Julia Okoroji, et al.
Blood
|
January 27, 2009
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma
Constantine S Tam, Roland Bassett, Celina Ledesma, et al.
American Journal of Hematology
|
January 23, 2023
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors
Elias J Jabbour, Koji Sasaki, Fadi G Haddad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2005
Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research
Steven Z Pavletic, Issa F Khouri, Michael Haagenson, et al.
Haematologica
|
January 29, 2008
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience
Paolo Anderlini, Rima Saliba, Sandra Acholonu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 12, 2016
Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
Paolo Anderlini, Rima M Saliba, Celina Ledesma, et al.
Blood
|
July 26, 2003
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
Naoto T Ueno, Yee Chung Cheng, Gabriela Rondón, et al.
Page
of 7